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Sinary Biodistribution of chimeric mouse/human monoclonal antibody against non-specific cross-reacting
antigen (chNCA Ab) was studied in athymic mice and patients with metastatic bone disease. 9=-rc-chNCA Ab
showed a high labelling efficiency, stability and also a high binding ratio to human granulocytes. Since NCA
showed cross-reactivity with carcinoembryonic antigen (CEA), animal experiments showed that 99"c-chNCA
Ab was accumulated in the xenografted tumour which expressed CEA, suggesting the preserved
immunoreactivity of labelled materials. In the clnical study, injected 99rc-chNCA Ab formed a high
molcular weight complex immediately after intravenous aministration and was trapped mainly in liver. The
first-phase plasma half-life was 6.4+ 1.1 min. None of the patients showed adverse reaction or human anti-
murine or anti-chimeric antibody in their serum. 99"lc-chNCA Ab demonstrated remarkably different
biodistribution between patients and the animal model and showed different pharmacokinetics from other
murine and chimeric Abs reported previously. For safety HPLC analysis should be performed before clinical
radioimmunodetection or radioimmunotherapy by incubating radiolabelled MAb with human serum under
strict conditions.
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Radiolabelled monoclonal antibodies (MAbs) are used for
the diagnosis and the therapy of cancer and some benign
diseases (Mach et al., 1980; Locher et al., 1986; Courtenay-
Luck et al., 1984). Production of the human anti-murine
antibody (HAMA) is one of the most serious problems as far
as murine MAbs are concerned. HAMA, produced in the
sera of patients who received murine MAbs repeatedly, may
result in the neutralisation of infused MAb or in allergic
reactions (Schroff et al., 1985; Shawler et al., 1985). Recent
developments in genetic engineering enable us to use chimeric
mouse-human MAbs which are expected to decrease the
HAMA production, since chimeric MAbs consist of mouse
variable regions and human constant regions (Boulianne et
al., 1984). However, there has been a report which describes
the production of HAMA in serum samples of metastatic
colorectal cancer patients after administration of chimeric
MAb designated B72.3 (Khazaeli et al., 1991).
Non-specific cross-reacting antigen (NCA) is expressed on
the surface of human granulocytes and cross-reacts with
carcinoembryonic antigen (CEA) (von Kleist et al., 1972).
Therefore, radiolabelled anti-NCA Ab has been successfully
used for the diagnosis of infectious diseases and bone
metastases of malignancies, although the distinction would
not be made between sites of inflammation and sites of
cancer expressing CEA (Locher et al., 1986; Reuland et al.,
1991; Munz et al., 1990).
In this study, chimenrc antibody against the NCA (chNCA
Ab) was labelled with 9Tc pertechnetate, since 99'Tc was an
ideal radionuclide for radioimmunodetection, and adminis-
tered into tumour-beanng athymic mice and patients to
compare the biodistribution. Patients with bone metastasis
from prostate cancer were chosen for the clinical application,
since prostate cancer often shows osteogenic metastasis,
which could be imaged as a photopenic area on the
immunoscintigraphy using radiolabelled anti-NCA Ab.
Materids and methods
Murine and chimeric mouse-human anti-NCA antibodies
Murine anti-NCA Ab (mNCA Ab), IgG, isotype, was
purified from ascites of Balb/c mouse inoculated intraper-
itoneally with hybridoma cells that were produced by the
fusion of mouse myeloma cells and anti-NCA Ab-producing
B-cells derived from Balb/c mouse immunised with CEA.
Derived mNCA Ab reacted to NCA 50 and NCA 90. chNCA
Ab was prepared by the method previously reported (Koga et
al., 1990). VY(VK) gene, isolated from hybridoma 2.7.1G.10.,
was linked to Cy(CK) gene from ARH77 human myeloma cell
line. Recombinant DNA was sequentially transfected into
p3x63-Ag8.653 mouse myeloma cell line by electroporation
(Potter et al., 1984). The transfectants were adapted to be
grown in Iscove's modified Dulbecco's medium supplemented
with bovine insulin (5 pg ml-'), human transferrin
(10 pg ml-') and ethanolamine (1.53 pg ml-') and then
cultured in a hollow fibre cell culture system (Cellmax 100,
Cellco Advanced Bioreactors, Kensington, MD, USA).
chNCA Ab was purified from the supernatant on SP-TOY
OPEAL (Tosoh, Tokyo, Japan), QAE-TOY OPEAL
(Tosoh), protein -A-Sepharose (Pharmacia, Uppsala, Swe-
den) and Sephacryl S-300 (Pharmacia) column.
MAb against human chorionic gonadotropin, IgG, was
used as an irrelevant control Ab. Serum samples obtained
from five patients who received 9'Tc-labelled murine MAb
against CEA, designated BW431/126 (Baum et al., 1989) were
used as control in the measurement of serum levels of
HAMA and human anti-chimera antibody (HACA).
Radiolabelling procedure
'Tc labelling 9Tc labelling was performed according to
the method reported previously (Mather and Ellison, 1990).
Purified mNCA Ab and chNCA Ab, I mg ml-' of 0.05 M
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phosphate-buffered saline (PBS), pH 7.5, were reduced by
4.8 pj of 97%, 2-mercaptoethanol (2-ME, Wako, Osaka,
Japan) with 2-ME/MAb molar ratio of 10000:1 at 25°C for
30 min. The reduced antibodies were then purified by gel
chromatography using G-25M Sephadex column (Pharma-
cia). The protein fraction was separated into 0.5 mg aliquots.
For 99'Tc labelling, 50 p1 of hydroxymethylene diphospho-
nate (HMDP, Nihon Medi-physics, Nishinomiya, Japan)
solution reconstituted with 5 ml of 0.9% sodium chloride
was added to 0.5 mg ofreduced antibody. Antibody-HMDP
mixture was then incubated with 740 MBq of 99"Tc
pertechnetate eluted from a 9Mo/9Tc generator (Daina-
bot, Tokyo, Japan) for 10 min. The labelling efficiency was
determined by the cellulose acetate electrophoresis and
quantitative measurement as reported previously (Watanabe
et al., 1994).
'"I labelling Radioiodination of both mNCA Ab and
chNCA Ab was performed by the chloramine-T method
(Hunter and Greenwood, 1962). In brief, 18.5MBq (5 p1) of
sodium ['2Jiodide was added to 40 pg of Ab in 180 y1 of
0.3 M phosphate buffer (PB), pH 7.5, followed by adding
10 Id ofchloramine-T solution (0.3 mg ml-' of 0.3 M PB, pH
7.5) and reacted for 5 min. Free '"I present in the reaction
mixture was separated from the labelled protein by gel
filtration on a G-25M Sephadex column (Pharmacia). Specific
activity of the radioiodinated MAbs was estimated as
approximately 430 MBq mg-'.
In vitro immunoreactivity and aninal experiments
Immunoreactivity of radiolabelled MAbs was determined by
the in vitro cell binding assay and in vivo tumour
accumulation studies using LS-180, human colorectal
carcinoma cells that expressed CEA molecule on their
surfaces. The cell binding assay was performed by incubating
radiolabelled MAbs (30 ng in 100p1 of 0.05 M PBS) with
increasing numbers of LS-180 (1 x 10- 1 x 107) in microcen-
trifuge tubes for 1 h at 250C. After centrifugation at
10 000 r.p.m. for 10 min, supernatant was aspirated. The
upper portion of tubes were cut and removed. The
radioactivity of cells located on the bottom of tubes was
counted by a well-type gamma-counter. The percentage of
radioactivity bound to cells was calculated.
Athymic nude mice bearing LS-180 human colorectal
cancer cells were used for studying in vivo immunoreactivity
and biodistribution of radiolabelled MAbs. Average weight
of tumours was 0.46 g at 2 weeks after inoculation of LS-180
(1 x 107 cells) subcutaneously into a rear flank. The mice were
injected intravenously with approximately 400 ng of both
"9'Tc-labelled and '25I-labelled MAbs. At 3 and 18 h post
injection, the mice were anaesthetised and sacrificed, and the
weight and radioactivity of major organs were measured.
Biodistribution was presented as a percentage of the injected
dose per gram of organ corrected for 20 g of body weight.
Four to five mice with tumours of a defined size were
examined in each group. Statistical analysis was made by
Student's t-test. Scintigrams of tumour xenograft were
obtained at 18 h after injection of high-dose 99-Tc-mNCA
Ab or 9Tc-chNCA Ab into mice with large tumours.
Binding to human granulocytes
Venous blood was collected from a normal volunteer in a
50 ml syringe containing 0.4 ml of heparin and 7 ml of
hydroxy ethylstarch, and sedimented at 1 xg for 60 min.
Supernatant was collected and centrifuged at 1000 r.p.m. for
5 min to separate leucocytes. Leucocytes were resuspended in
autologous plasma. A 10-fold dilution was repeated three
times and the number of granulocytes were measured by flow
cytometry and cytochemical analysis using Technicon
(Technicon Instruments, Tarrytown, NY, USA). Radiola-
belled MAbs (30 ng in 0.05 M PBS) were incubated with
increasing numbers of granulocytes (7.4x 103-7.4x 106) in
microcentrifuge tubes for 1 h at 25C. The percentage of
radioactivity bound to granulocytes was calculated in the
same manner with the cell binding assay.
Clinical study'
Four patients (63 to 74 years of age) with metastatic bone
tumour from prostate cancer were studied. All patients
gave informed consents to participate in the study which
was approved by the ethical committee of our university.
9Tc-chNCA Ab (1110 MBq, 1 mg) was mixed with
100 ml physiological saline followed by the intravenous
injection for 10 min. Temperature, blood pressure, heart
rate, respiratory rate and subjective symptoms were
monitored before, during and until 30 min after the
infusion.
Scintigraphy was performed using a gamma camera (ZLC
7500, Siemens, IL, USA) fitted with a low-energy all-purpose
collimator. On-line computer Scintipac 700 (Shimadzu,
Kyoto, Japan) was used for processing the image data.
Following dynamic imaging of abdomen anteriorly for
30 min from the beginning of injection, anterior and
posterior planar images of the chest, abdomen and pelvis
were obtained at 1, 4 and 24 h after injection.
Pharmacokinetics and inmune response
Blood samples were collected sequentially at 5, 10, 15, 20, 25,
30 and 60 min, 4 and 24 h after injection of 9'Tc-chNCA
Ab. Radioactivity of whole-blood samples and plasma
samples were counted with a gamma counter to determine
the blood clearance of 9Tc-chNCA Ab. High-pressure
liquid chromatography (HPLC) analysis was performed
using 5 min and 30 min plasma samples with a G3000SW
column (Tosoh). Blood samples were also obtained at
intervals from 2 to at least 19 weeks to investigate the
serological immune response to the injected chNCA Ab.
Detection of HAMA in the serum samples after injection
of 9Tc-chNCA Ab was performed by the radioimmunoas-
say as reported previously (LoBuglio et al., 1986; Khazaeli et
al., 1991). Serum samples (100 p1) were incubated with
mNCA Ab-coated beads for 90 min at 25-C. After washing
twice with purified water, '151-mNCA Ab was added and
incubated for 60 min at 25°C. Purified water was then added
and unbound radioactivity was washed away. Radioactivity
bound to beads was counted with a gamma counter. HAMA
was determined as positive when bound radioactivity to
beads was over the mean values plus three standard
deviations of 20 normal individuals. For the assay of
HACA, the same procedure was applied using chNCA Ab
instead of mNCA Ab. The same criteria were applied to
categorise as a positive HACA response. Sera obtained from
20 healthy individuals and five patients receiving 9Tc-
BW431/26 (Oriuchi et al., 1995) were also examined, and
their HAMA and HACA titres were determined. Three of
five patients receiving 99Tc-BW431/26 developed HAMA
detectable with this method.
HPLC analysis of9Tc-chNCA Ab incubated with hwnan
serun
In order to assess the interaction of 99'Tc-chNCA Ab with
the human serum, 99Tc-chNCA Ab was incubated with
human serum in vitro for 1 h at 37CC and HPLC analysis
was performed with a G3000SW column (Tosoh) eluted at a
flow rate of 1 ml min-' and 0.5 ml fractionation. Doses of
'Tc-chNCA Ab used for the incubation were: (1) 5 pg of
99"Tc-chNCA Ab with 20 p1 of human serum, which was
performed as one of the preclinical tests before the clinical
trial; and (2) 5 ng of 9Tc-chNCA Ab with 20 i1 of human
serum, which was performed to confirm the presence of high
molecular weight complex after the clinical trial. The latter
dosage (2) was calculated as equivalent to that of the clinical
situation.
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Results
The cellulose acetate electrophoresis of 9'Tc-chNCA Ab
showed that labelling efficiency was more than 96% and there
was no evidence of colloid formation. Specific activities of
'Tc-labelled mNCA Ab and chNCA Ab were calculated as
1.5 GBq mg-'. The cell binding assay showed that the
percentage binding of 'Tc-chNCA Ab to LS-180 cells
increased as the cell number increased (Figure 1, top) and it
was almost comparable with 15I-chNCA Ab and 'Tc-
mNCA Ab. Percentage binding of 9Tc- and '"1-labelled
chNCA Ab to human granulocytes also increased in
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proportion to granulocyte numbers added, and 73.4% and
66.7% of bound radioactivity were obtained at granulocyte
numbers of 7.4 x 106 per tube (Figure 1, bottom). 992Tc-
labelled chNCA Ab and mNCA Ab showed a slightly
different biodistribution in athymic mice bearing LS-180 as
shown in Table I. Clearance of 'Tc-chNCA Ab from the
circulation was faster than that of 'Tc-mNCA Ab resulting
in a lower radioactivity of 'Tc-chNCA Ab (% injected dose
per gram tissue) in all organs except kidney. Tumour-
normal organ ratio was high with mTc-chNCA Ab except
tumour-kidney ratio. At 18 h after injection of "mTc-
chNCA Ab, tumour-blood ratio was 1.74; tumour-liver,
2.73; tumour-muscle, 13.7; whereas the ratios for 99Tc-
chNCA Ab were 0.74, 1.62 and 6.89 respectively. Tumour-
kidney ratios for 'Tc-labelled chNCA Ab and mNCA Ab
were 0.33 and 0.87 respectively. Scintigrams of athymic mice
confirmed the results of biodistribution studies, showing a
higher radioactivity in the tumour and kidney of mice
administered with 99'Tc-chNCA Ab (Figure 2).
Four patients with bone metastases received 'Tc-chNCA
Ab and no adverse reaction was noted after the administra-
tion in these patients. Dynamic images obtained immediately
after injection demonstrated intense radioactivity in the liver
Cell counts
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Fgre 1 Immunoreactivity of 9Tc-chNCA Ab (-v), '2I-
chNCA Ab (- -0- -), 'Tc-mNCA Ab (--
---- -), '251-mNCA
Ab (A-). 99Tc-labelled control murine Ab (---) and 1251-
labelled control murine Ab (- -) evaluated by in vitro binding to
human colorectal cancer cells (top) and to human granulocytes
(bottom).
Fgre 2 Scintigrams of athymic mice carrying human colorectal
cancer cell xenograft (arrow) at 18 h after administration of
99mTc-mNCA Ab (left) and "mTc-chNCA Ab (right). Arrow-
heads: kidneys.
Table I Biodistribution of 99Tc- and 125I-labelled chNCA Ab and mNCA Ab in athymic mice carrying human colorectal
cancer cells at 3 and 18h after intravenous administration.
3h 18h
99-Tc-chNCA '25I-chNCA 99-Tc-mNCA '25I-m.N'CA 99-Tc-chNCA '25I-ch.NVCA 99-Tc-m.NCA I5I-mNCA Organ (n = 4) (n =4) (n = 4) 'n = 4} (n = 5) (n = 5) (n = 4) (n = 4)
Blood 16.7+2.0 17.7+0.9 20.8+1.4a 17.5+0.7 2.6+0.5 5.4+ .lb 6.7+0.8a 5.5+0.9a
Liver 4.8+0.5 6.0+1.2 9.1 + 1.2b 6.6+1.1 2.3+1.0 1.8+0.4 6.5+0.9a 2.4+0.7
Kidney 19.3+2.0 8.0+ 1.3a 12.5+ .1b 7.4+1.la 17.6+4.3 2.5+0.7a 13.9+1.2 2.4+0.2a
Intestine 3.2+0.5 2.3+0.7 2.3+0.2 2.5+0.5 2.1+0.6 1.4+0.9 2.1+0.4 1.1+0.3
Stomach 1.2+0.6 4.4+2.0 1.2+0.1 3.8 + 1.9 1.4+0.8 2.8+ 1.3 1.3+0.3 2.5+1.2
Spleen 3.9+1.3 6.2+3.0 7.2+1.4 6.4+1.4 1.5t0.4 2.1+0.5 3.5+1.6 2.1+0.8
Lung 7.5+3.2 8.7+4.1 9.0+5.1 8.2+4.3 1.8+0.8 3.0+1.0 2.6+0.5 2.2+0.5
Muscle 0.7+0.2 1.0+0.3 1.1 +0.3 0.8+0.3 0.2+0.02 0.4+0.07b 0.6+0.2b 0.5+0.1b
Bone 1.8+0.2 2.6±0.8 3.0+0.6 2.8+0.7 0.6+0.1 0.9+0.2 1.5+0.4b 1.0+0.2b
Tumour 7.7±1.3 8.7±1.0 10.0+0.8 7.6+0.9 5.4+2.7 6.8+3.8 9.8+1.3 6.7+0.8
ap<0 001 compared with99Tc-chNCA. bp<0.01 compared with 99mTc-chNCA.
Data are shown as % injected dose per g oforgans (mean+s.e.).
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_(data not shown). Static images of a patient demonstrated
remarkable accumulation of the tracer in liver accompanied
by moderate accumulation in spleen. lung and kidney (Figure
3). Metastatic bone lesion could be seen as a photopenic area
on 1 and 4 h posterior images (Figure 4). Blood clearance of
Figure 3 Anterior static images obtained 1. 4 and 24h after
administration of9*mTc-chNNCA Ab in a 64- ear-old patient with
metastatic bone tumour from prostate cancer. Intense radio-
activity was seen in the lher.
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the radioactivitv in four patients demonstrated that the
biphasic curve was found to be best fitted with the first-phase
half-life of 6.4+ 1.1 min (mean+s.d.) and the second-phase
half-life of 70.8 +41.6 h (Figure 5). Figure 6 represents the
HPLC elution profile of plasma samples of a patient obtained
at 5 and 30 min after injection of 'Tc-chNCA Ab. More
than 60% of the plasma radioactivitv A-as found at the first
peak at around 29 min of the retention time corresponding to
a high molecular weight material in the circulation.
HPLC analI sis show-ed that there A-as the first peak before
the second peak of 'Tc-chNCA Ab under incubation
condition similar to those pertaining to the clinical situation
(5 ng of 9'9Tc-chNCA Ab with 20 MI serum). which indicated
the evidence of a high molecular weight complex formation.
However. there w-as apparently no complex formation when
I x 10"-fold excess of 9Tc-chNCA Ab was incubated w-ith
serum (5 jg of 9Tc-chNCA Ab with 20 ,l serum) as shou-n
in Figure 7.
No patient showed positive HACA or HAMA response in
their sera within 19 weeks after injection of 9'9Tc-chNCA Ab.
whereas 60% of patients produced HAMA in their sera after
injection of the same dose of 9Tc-BW431 26 (Figure 8).
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Figure 5 Blood clearance of 9)Tc-chN-CA Ab in four patients
with metastatic bone tumour. A biphasic curVe fitting w-as
demonstrated with mean first-phase half-life of 6.4min and
second-phase half life of 70.8 h.
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Figure 4 Postenror static images obtained I and 4 h after
administration of )Tc-chNNCA Ab and 9Tc-HMDP bone
scintigraphy in the same patient as Figure 3. Metastatic bone
lesion can be seen as a vague photopenic area on 99mTc-chNCA
Ab images (arrows). and a hotspot on bone scintigraphx
(arrowhead).
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Figure 6 HPLC elution profile of plasma dravvn at 5min (- -)
and 30min (-- - ----) after the admimnstration of 99Tc-chNCA
Ab.Biodisbibution of chwneric Ab h moce and human
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Figure 7 HPLC elution profiles of 99Tc-chNCA Ab after
incubation with normal human serum for 60min. 99Tc-chNCA
Ab and normal human serum were incubated under two different
chNCA Ab to serum ratios: 5pg of 99ITc-chNCA Ab with 20p1
serum (---); 5 ng of99Tc-chNCA Ab With 20,ul serum (--0 - -).
Normal
controls
(n = 20)
Normal
controls
(n = 20)
HAMA
0
6
i
Patients after Patients after
99mTc-chNCA Ab 99mTc-mCEA Ab
(n=5) (n=5)
HACA
a I 0
Patients after Patients after
'Tcc-chNCA Ab 99mTc-mCEA Ab
(n= 5) (n= 5)
Figure 8 Human anti-mouse antibody (HAMA) and human
anti-chimera antibodv (HACA) levels in serum of normal
controls, patients receiving 9Tc-chNCA Ab and 99rTc-
BW431 26. murine anti-CEA Ab. Dotted lines indicate the
normal ranges obtained from healthy individuals.
Discussion
Chimenrc anti-NCA Ab was successfullv labelled with 9'9Tc
with high specific activity of 1.5 GBq mg-1. <'I and ...In have
been conjugated with MAb and used for radioimmunodetec-
tion. '"Tc is relatively new for conjugating MAb. especially
for chimeric MAb. However. 'Tc has several advantages for
imaging. 'Tc is easily axvailable since it is produced by a
generator system and photon energy is suitable for gamma
camera imaging. The relatively short half-life of9Tc enables
sufficient amount of injection dose to provide tomography
with a high resolution and low statistical error.
Animal experiments showed that 'Tc-chNCA Ab was
accumulated in the xenografted tumour which expressed
CEA. In contrast to animal studies, clinical examination
revealed that most radioactivity was present in the liver
immediately after intravenous injection of 99ITc-chNCA Ab.
Blood clearance of 9'9Tc-chNCA Ab showed a biphasic
clearance with the first-phase haW-life of 6.4+ 1.1 mn,.
although reported mean half-lives of chimeric MAbs in
humans were approximately 18 h (first phase) and 100 h
(second phase). six times longer than those of murine MAbs
(LoBuglio et al.. 1989: Meredith et al.. 1991). HPLC analysis
of plasma from the patient who received 9Tc-chNCA Ab
revealed the formation of a high molecular weight complex in
the circulation and there was no increment in free 9'Tc
pertechnetate in the plasma detected by either whole body
imaging or HPLC analysis. NCA has been found in various
human tissues such as lung. spleen. granulocytes and also in
the serum with a variety of molecular weights ranging from
50 to 160 kDa (von Kleist et al.. 1972; Bosslet et al.. 1985). In
vivo instability of reduction-mediated 'Tc-labelled Ab has
been reported (Sakahara et al.. 1993) but no evidence of
aggregation or complex formation was noted x-hen 'Tc-
chNCA Ab was incubated With PBS (data not shown).
HPLC analysis of the diluted 'Tc-chNCA Ab incubated
With normal human serum in vitro demonstrated the same
radioactivity peak corresponding to a high molecular %veight
complex (Figure 7). Serum samples. which were absorbed by
anti-NCA Ab and then incubated with 'Tc-chNCA Ab.
showed only one peak which corresponded to 9'9Tc-chNCA
Ab (data not shown). From these results. increased radio-
activity in the liver is supposed to be caused by the complex
formation of injected 'Tc-chNCA Ab with circulating NCA
resulting in subsequent clearance by the reticuloendothelial
system. Of note wxas the fact that a high molecular A-eight
complex A-as only detected by HPLC under a certain
incubation ratio of radiolabelled MAb to human serum.
According to the recommendation of the Food and Drug
Administration in USA (Center for Biologics Evaluation and
Research. FDA 1993). 'Tc-chNCA Ab was examined for
binding to serum protein using HPLC by incubating 'Tc-
chNCA Ab with human serum as a preclinical safety testing.
though the high molecular weight complex was hardly
demonstrable probably because of the saturation of
antigen-bimding capacity present in the serum. On the
contrary, when 'Tc-chNCA Ab and human serum were
incubated under the strict dilution ratio (1 x 103-fold). which
was the equivalent ratio of 'Tc-chNCA Ab to serum in the
circulation. then a high molecular weight complex was clearly
demonstrated by HPLC.
The biodistribution proffle observed in this study was
different from other studies. The disparity between the results
of the biodistribution of '"'I-labelled MAb in man and mice
has been reported (Ledermann et al.. 1993). In the report.
most of the radioactivitx was located in the bone marrow and
spleen. since the radiolabelled MAb was bound to circulating
granulocytes. Lack of immunodetection and complications
associated With MAb cross-reactive with circulating cells had
been reported (Diliman et al.. 1984).
Several authors has-e suggested that the presence of
antigen in the blood does not significantly affect the results
of imaging, though it would form a circulating immune
complex (Goldenberg et al.. 1978: Mach et al.. 1980: Primus
et al.. 1980). Pharmacokinetics and biodistnrbution of .'.In-
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labelled MAb which formed a circulating immune complex
have been reported (Hnatowich et al., 1987; Davidson et al.,
1991). In the present study, increased liver uptake of
radiolabelled MAb was noted as in the previous studies,
although the pharmacokinetics were different and imaging
was not successful. Blood clearance of "Tc-chNCA Ab was
much faster than in other studies and the mechanism of fast
clearance and the liver accumulation of 9'9Tc-chNCA Ab
remains to be clarified.
None of the patients produced HAMA or HACA within
19 weeks after 99mTc-chNCA Ab injection, although three of
five patients who received the same 1 mg of 99Tc-labelled
murine Ab produced HAMA in their serum. There have been
a few reports describing the immunogenicity ofchimeric Abs.
Chimeric Abs designated 17-lA, L6 and NR-LU-13 had low
immunogenicity, whereas '31I-labelled chimeric Ab, B72.3,
had considerable immunogenicity (Khazaeli et al., 1991;
LoBuglio et al., 1989; Meredith et al., 1991). In the latter
paper, seven of 12 patients with metastatic colon cancer had
an antibody response after intravenous injection of 3.4 to
6.9 mg of chimeric B72.3, and a small portion of the
antibody response was directed to epitopes requiring the
presence of both murine V-region and human CH-1/Kc
constant regions. These results may indicate that the
inmunogenicity of chimeric Abs may depend on the amino
acid sequences of murine V-region.
In conclusion, chNCA Ab was stably labelled with 'Tc
pertechnetate and immunoreactivity was completely reserved
with high-binding capacity to human granulocytes and CEA-
expressing colon cancer cells. 99'c-chNCA Ab was safely
administered to patients without generating HAMA or
HACA response. In contrast to animal studies, however,
circulating antigenic molecules reactive with chNCA Ab
formed a high molecular weight complex immediately after
the administration of99mTc-chNCA Ab and were taken up in
the liver. For safety HPLC analysis should be performed
before clinical radioimmunodetection or radioimmunother-
apy by incubating radiolabelled MAb with human serum
under strict conditions.
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